Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 2 (1)

Trial Status

Active Not Recruiting2
Recruiting1
Withdrawn1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04467021Not ApplicableActive Not Recruiting

Cancer and Blood Pressure Management, CARISMA Study

NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04216732Recruiting

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

NCT04106843Phase 2Withdrawn

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Showing all 4 trials

Research Network

Activity Timeline